Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Common Equity (2016 - 2025)

Corcept Therapeutics' Common Equity history spans 10 years, with the latest figure at $647.8 million for Q4 2025.

  • For Q4 2025, Common Equity fell 4.68% year-over-year to $647.8 million; the TTM value through Dec 2025 reached $647.8 million, down 4.68%, while the annual FY2025 figure was $647.8 million, 4.68% down from the prior year.
  • Common Equity for Q4 2025 was $647.8 million at Corcept Therapeutics, up from $631.9 million in the prior quarter.
  • Across five years, Common Equity topped out at $683.3 million in Q1 2025 and bottomed at $375.8 million in Q4 2021.
  • The 5-year median for Common Equity is $526.1 million (2021), against an average of $537.8 million.
  • The largest annual shift saw Common Equity dropped 28.19% in 2021 before it surged 41.42% in 2024.
  • A 5-year view of Common Equity shows it stood at $375.8 million in 2021, then soared by 33.54% to $501.8 million in 2022, then grew by 0.97% to $506.7 million in 2023, then soared by 34.12% to $679.6 million in 2024, then decreased by 4.68% to $647.8 million in 2025.
  • Per Business Quant, the three most recent readings for CORT's Common Equity are $647.8 million (Q4 2025), $631.9 million (Q3 2025), and $635.8 million (Q2 2025).